- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Anne L. Schwartz on Medicaid's Role in Addressing the Opioid Epidemic and Social Determinants of Health
Medicaid programs have been working to address to opioid epidemic in a number of ways and is starting to get involved in addressing social determinants of health, explained Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission.
Medicaid programs have been working to address to opioid epidemic in a number of ways and is starting to get involved in addressing social determinants of health, explained Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission.
Transcript
What has Medicaid’s role been in combating the opioid epidemic?
Medicaid programs have been working to address the opioid epidemic in a number of different ways. The first is obviously providing coverage for people who weren’t previously covered, and covering the treatment services associated with their substance use disorder. Medicaid programs have also been working with other state agencies, for example, pharmacy boards, to have better monitoring of prescribing practices and limits on the availability of prescription opioids.
What is the importance of addressing social determinants of health?
So, this is an area that I think is still really evolving. The research literature is pretty strong about the impact of different factors, such as education, poverty, living close to environmental hazards and the impact on health. The thing that’s tricky in the Medicaid program is that it is a program that provides medical assistance. And I think what you’re seeing now, states, health plans, advocates and others trying to sort it out what is basically an insurance vehicle to try and address some of these factors that affect health that are not normally a part of a health insurance package.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
